HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Cancer treatment clears two Australian patients of HIV

    Scientists have uncovered two new cases of HIV patients in whom the virus has become undetectable. The patients' virus levels became undetectable after bone-marrow therapy with stem cells.

    20 July 2014 | Nature
  • Three Top Researchers Question Efavirenz Status as First-Line Agent

    Looking at recent evidence, three top clinical investigators question whether the nonnucleoside efavirenz should maintain its rank as a preferred first-line antiretroviral.

    14 July 2014 | International AIDS Society
  • Common HIV Drug May Boost Suicide Risk

    A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.

    02 July 2014 | Web MD
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
  • Lowering toxicity of new HIV drugs predicted to improve life expectancy

    While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals.

    26 June 2014 | EurekAlert
  • Mortality with HIV drops sharply in Georgia after 2004 cART rollout

    Mortality among Georgians with HIV fell by more than half after 2004, when the Eastern European country began providing combination antiretroviral therapy (cART) to everyone in need. Tuberculosis remains a leading cause of death.

    23 June 2014 | International AIDS Society
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
  • South Africa: Antiretrovirals Credited for TB Decline

    South Africa is seeing about 79,000 fewer TB cases annually thanks to increased HIV treatment uptake, according to the latest research from the National Institute for Communicable Diseases (NCID)

    13 June 2014 | Health-e
  • First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

    Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

    06 June 2014 | Merck
  • Five-drug ART has no advantage over three drugs for early HIV

    Starting antiretroviral therapy (ART) with five drugs instead of three offered no virologic or immunologic advantage in people with early HIV infection, according to results of a randomized trial.

    04 June 2014 | International AIDS Society
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.